Microsoft-led study reveals AI biosecurity gaps in genetic screening

Twist Bioscience (TWST) co-authored a Science study with Microsoft, revealing that AI-designed protein variants can bypass current biosecurity screening, necessitating advanced detection protocols, which TWST and partners have subsequently developed. This positions the $1.8 billion biotech company at the forefront of addressing evolving biosecurity challenges. Financially, TWST reported an 18% YoY Q3 2025 revenue increase to $96.1 million, with an improved adjusted EBITDA loss of $8 million, and maintains a robust balance sheet, contributing to a recent 9.4% stock gain despite mixed analyst price target adjustments.

Analysis

Twist Bioscience (TWST) has strategically positioned itself at the forefront of the emerging AI-driven biosecurity field, as evidenced by its co-authored research in Science with Microsoft (MSFT). The study reveals a critical vulnerability in standard biosecurity screening to AI-designed proteins, but more importantly, highlights TWST's proactive development of enhanced detection protocols to mitigate this risk. This technological leadership is complemented by a strengthening financial profile. The company reported an 18% year-over-year revenue increase to $96.1 million in Q3 2025, building on 23% trailing-twelve-month growth. While still unprofitable, its adjusted EBITDA loss improved to $8 million. The balance sheet remains a key strength, characterized by a cash position exceeding debt and a robust current ratio of 3.9x, underpinning its 'GOOD' Financial Health score from InvestingPro and providing significant operational flexibility. This combination of strategic positioning and improving fundamentals has likely contributed to the stock's recent 9.4% weekly gain. However, the outlook is tempered by mixed signals from analysts; despite Buy/Outperform ratings from TD Cowen and Evercore ISI, all three cited firms lowered their price targets, with conflicting commentary on the performance and guidance for the Next-Generation Sequencing (NGS) segment, introducing a layer of uncertainty.

Key Decisions for Investors

• Investors should consider the long-term value of Twist Bioscience's leadership in the critical AI and biosecurity space, which could provide a significant competitive moat and future growth avenues not fully captured by current financials.
• While revenue growth is strong and the balance sheet is robust, the company's path to positive EBITDA remains a key catalyst to monitor; the improvement to an $8 million adjusted EBITDA loss is positive but continued progress is essential.
• The divergence in analyst price targets and rationales, particularly concerning the outlook for NGS revenue, suggests near-term volatility and warrants a cautious approach, focusing on future earnings calls for clarity on guidance.